The subsequent acquisition of leukemogenesis-driving abnormalities such as NPM1 or IDH1/2 mutations could lead to the sudden development of de novo AML without passing through CP-CML. Here, NPM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.